0R15 7793.0 0.1028% 0R1E 7575.0 -1.8782% 0M69 None None% 0R2V 174.0 1.6058% 0QYR 1387.5 0.7991% 0QYP 397.5 0.7605% 0LCV 137.1211 0.3815% 0RUK None None% 0RYA 1752.0 0.0% 0RIH 165.6 0.3941% 0RIH 164.7 -0.5435% 0R1O 181.75 10110.6742% 0R1O None None% 0QFP None None% 0M2Z 298.95 0.302% 0VSO None None% 0R1I None None% 0QZI 434.5 -0.344% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-02T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -650.50000M | 379.53M | -348.05600M | 67.31M | -164.42800M |
| Minority interest | - | - | - | - | - |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Selling general administrative | 102.46M | 102.80M | 88.21M | 63.49M | 48.29M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -109.81400M | 913.08M | 0.54M | 289.59M | 3.12M |
| Reconciled depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Ebit | -697.33300M | 355.57M | -354.43500M | 42.02M | -162.46200M |
| Ebitda | -673.16100M | 373.53M | -345.25100M | 46.74M | -158.94300M |
| Depreciation and amortization | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Non operating income net other | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Operating income | -673.16100M | 373.53M | -354.43500M | 46.74M | -158.94300M |
| Other operating expenses | 673.60M | 539.55M | 354.98M | 242.85M | 162.07M |
| Interest expense | -46.83300M | 23.96M | 6.38M | 25.29M | 0.00000M |
| Tax provision | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Interest income | - | - | - | 5.47M | 4.28M |
| Net interest income | - | - | - | - | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.32500M | 1.87M | 0.81M | 0.45M | 0.55M |
| Total revenue | 0.44M | 913.08M | 0.54M | 289.59M | 3.12M |
| Total operating expenses | 563.35M | 539.55M | 354.98M | 242.85M | 162.07M |
| Cost of revenue | 110.25M | - | - | 179.36M | 113.77M |
| Total other income expense net | 22.66M | 6.00M | 6.38M | 20.57M | -5.48500M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Net income applicable to common shares | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2243.06M | 2751.88M | 1827.97M | 1066.75M | 489.02M |
| Intangible assets | 0.07M | 0.12M | 0.18M | 0.23M | 0.29M |
| Earning assets | - | - | - | - | - |
| Other current assets | 37.71M | 38.08M | 26.14M | 43.68M | 9.66M |
| Total liab | 367.58M | 352.42M | 163.73M | 127.33M | 96.82M |
| Total stockholder equity | 1875.48M | 2399.46M | 1664.23M | 939.42M | 392.19M |
| Deferred long term liab | - | - | - | - | 11.05M |
| Other current liab | 65.51M | 91.90M | 71.46M | 41.71M | 0.22M |
| Common stock | 2.44M | 2.39M | 2.28M | 1.85M | 1.58M |
| Capital stock | 2.44M | 2.39M | 2.28M | 1.85M | 1.58M |
| Retained earnings | -846.09000M | -195.91500M | -573.57600M | -224.71100M | -291.56900M |
| Other liab | 18.29M | 19.66M | 19.41M | 26.17M | 69.08M |
| Good will | - | - | - | - | - |
| Other assets | 16.27M | 22.20M | 18.14M | 6.14M | 3.83M |
| Cash | 211.88M | 923.03M | 1168.62M | 943.77M | 456.65M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 121.11M | 119.88M | 94.26M | 57.11M | 27.75M |
| Current deferred revenue | 12.32M | 1.01M | 2.34M | 0.96M | 57.78M |
| Net debt | 32.14M | -698.00100M | -1107.19100M | -891.23200M | -456.64900M |
| Short term debt | 15.84M | 12.16M | 11.36M | 8.49M | -35.32400M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 244.02M | 225.03M | 61.43M | 52.54M | - |
| Other stockholder equity | 2734.78M | 2598.05M | 2235.62M | 1162.28M | 682.19M |
| Property plant equipment | 163.63M | 137.57M | 42.16M | 72.83M | 18.50M |
| Total current assets | 1853.03M | 2417.51M | 1716.62M | 987.55M | 466.39M |
| Long term investments | 53.13M | - | - | - | - |
| Net tangible assets | 1875.48M | 2399.46M | 1664.05M | 939.19M | 391.91M |
| Short term investments | 1603.43M | 1456.10M | 521.71M | - | - |
| Net receivables | 4.64M | 0.30M | 0.14M | 0.10M | 0.09M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 27.43M | 14.82M | 9.09M | 5.94M | 5.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -15.64700M | -5.06700M | -0.08300M | 0.00700M | -0.00800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 2.44M | 2.39M | 2.28M | 1.85M | 1.58M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -846.09000M | -195.91500M | -573.57600M | -224.71100M | -291.56900M |
| Treasury stock | -0.06300M | -0.06300M | -0.06300M | -0.06300M | -0.05700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 16.27M | 22.20M | 18.14M | 6.14M | 3.83M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 390.03M | 334.36M | 111.35M | 79.20M | 22.62M |
| Capital lease obligations | 244.02M | 225.03M | 61.43M | 52.54M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -258.65500M | -953.72500M | -522.81200M | 1.32M | -2.77300M |
| Change to liabilities | 3.64M | 32.21M | 15.24M | 30.01M | 12.36M |
| Total cashflows from investing activities | -258.65500M | -1035.43000M | -541.17000M | 1.32M | -2.77300M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 38.59M | 250.94M | 1016.15M | 430.98M | 315.93M |
| Change to operating activities | 15.39M | -9.71100M | 6.36M | -8.29800M | -3.80200M |
| Net income | -650.17500M | 377.66M | -348.86500M | 66.86M | -164.98100M |
| Change in cash | -715.88400M | -245.52400M | 236.66M | 489.00M | 216.90M |
| Begin period cash flow | 939.94M | 1185.47M | 948.81M | 459.81M | 242.91M |
| End period cash flow | 224.06M | 939.94M | 1185.47M | 948.81M | 459.81M |
| Total cash from operating activities | -495.74100M | 538.97M | -238.36600M | 56.68M | -96.23900M |
| Issuance of capital stock | 0.97M | 213.27M | 982.29M | 415.02M | 307.05M |
| Depreciation | 24.17M | 17.95M | 9.18M | 4.72M | 3.52M |
| Other cashflows from investing activities | - | - | - | 8.01M | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | -37.51400M | -25.74700M | -5.02500M | 332.30M |
| Change to account receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Sale purchase of stock | 38.59M | 250.94M | 1016.15M | 430.98M | -0.05700M |
| Other cashflows from financing activities | 37.62M | 37.68M | 33.86M | 15.96M | 8.94M |
| Change to netincome | 110.42M | 102.39M | 67.88M | 49.52M | 34.82M |
| Capital expenditures | 37.19M | 81.70M | 18.36M | 6.68M | 2.77M |
| Change receivables | 0.30M | -0.16100M | -0.04500M | -0.01100M | 2.54M |
| Cash flows other operating | 15.90M | -5.18900M | 18.25M | -94.42700M | 15.51M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -715.80400M | -245.51300M | 236.62M | 488.99M | 216.92M |
| Change in working capital | 19.84M | 26.86M | 33.44M | -48.43000M | 10.55M |
| Stock based compensation | 97.95M | 102.39M | 66.02M | 44.06M | 34.98M |
| Other non cash items | 12.47M | 14.11M | 1.86M | -10.53300M | 15.41M |
| Free cash flow | -532.92900M | 457.27M | -256.72400M | 49.99M | -99.01200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRSP Crispr Therapeutics AG |
1.26 2.34% | 55.07 | - | 23.36 | 28.27 | 2.80 | 19.62 | -7.3699 |
| NVO Novo Nordisk A/S |
-5.19 4.02% | 124.02 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.236 1.77% | 124.22 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.98 0.49% | 400.16 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
1.91 2.14% | 91.05 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Baarerstrasse 14, Zug, Switzerland, 6300
| Name | Title | Year Born |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Director | 1979 |
| Mr. Brendan Smith M.B.A. | Sr. VP, CFO & Principal Accounting Officer | 1976 |
| Dr. Lawrence Otto Klein Ph.D. | Chief Operating Officer | 1982 |
| Mr. James R. Kasinger | Gen. Counsel & Sec. | 1972 |
| Dr. Rodger Novak M.D. | Founder, Chairman & Pres | 1967 |
| Mr. Shaun Foy | Founder | NA |
| Dr. Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member | NA |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | NA |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | NA |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...